VACCライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (7 11月 2023 @ 06:00):

Stats
本日の出来高	163 052
平均出来高	731 881
時価総額	192.73M
EPS	$0.220 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.45
ATR14	$0.559 (17.75%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Pelletier Nadege	Buy	105 000	Share Option (Right to Buy)
2024-01-02	Griffiths Graham	Buy	96 500	Share Option (Right to Buy)
2024-01-02	Enright William	Buy	443 981	Share Option (Right to Buy)
2024-01-02	Brown Gemma	Buy	193 000	Share Option (Right to Buy)
2023-06-26	Scheeren Joseph	Buy	10 000	Ordinary Shares

INSIDER POWER
41.25
Last 95 transactions
Buy: 18 963 250 \| Sell: 20 685 755

ボリューム相関

長: 0.07 (neutral)

短: 0.52 (weak)

Signal:(49.914) Neutral

Vaccitech plc 相関

10 最も正の相関
SVOK	0.919
PAIC	0.901
FORE	0.872
RDUS	0.87
SVAC	0.858
RMRM	0.857
SPRT	0.835
TLGT	0.834
EPZM	0.829
IVA	0.828

10 最も負の相関
NETE	-0.908
BOCH	-0.876
RAVN	-0.866
AMRB	-0.862
HRMY	-0.852
SBBP	-0.847
MMAC	-0.843
CFMS	-0.835
SFST	-0.829
AEPPZ	-0.827

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Vaccitech plc 相関 - 通貨/商品

-0.16
( neutral )

0.30
( neutral )

0.00
( neutral )

-0.05
( neutral )

0.32
( neutral )

0.12
( neutral )

Vaccitech plc 財務諸表

Annual	2022
収益:	$44.70M
総利益:	$2.35M (5.26 %)
EPS:	$0.140

FY	2022
収益:	$44.70M
総利益:	$2.35M (5.26 %)
EPS:	$0.140

FY	2021
収益:	$268 000
総利益:	$268 000 (100.00 %)
EPS:	$-1 067.56

FY	2020
収益:	$4.82M
総利益:	$0.00 (0.00 %)
EPS:	$-371.62

Financial Reports:

No articles found.

Vaccitech plc

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.